IOVA
IOVANCE BIOTHERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$8.48
−11.30%Oct 16, 2026, 21:15 UTC
Iovance Biotherapeutics approved inducement stock options covering 111,615 shares of its common stock for 21 new non-executive employees.
Source:Sep 30, 2026, 15:26 UTC
Iovance Biotherapeutics stock hit a 52-week high after the company raised its 2026 revenue outlook to $410-$420 million on strong demand for its marketed therapies.
Source:Sep 29, 2026, 11:00 UTC
Iovance Biotherapeutics raised its full year 2026 total revenue guidance to $410-$420 million, up $55 million at the midpoint from the prior $350-$370 million range, citing strong U.S. demand for Amtagvi and Proleukin.
Sep 18, 2026, 21:10 UTC
Iovance Biotherapeutics approved inducement stock option grants covering 179,750 shares of common stock to eighteen new non-executive employees on September 17, 2026.
Source:Sep 15, 2026, 08:00 UTC
Shares of Nutex Health, AtriCure, Iovance Biotherapeutics, Centene and Concentra Group Holdings all reached 52-week highs on Monday, September 14, 2026.
Aug 21, 2026, 21:15 UTC
Iovance Biotherapeutics granted inducement stock options covering 240,135 shares of common stock to twenty new non-executive employees on August 20, 2026.
Source:Aug 6, 2026, 11:01 UTC
The FDA granted Fast Track Designation to Iovance Biotherapeutics for Lifileucel in soft tissue sarcomas.
Source:Aug 6, 2026, 11:01 UTC
Iovance Biotherapeutics reported record second quarter 2026 revenue of approximately $99 million, up 66% year-over-year, with U.S. Amtagvi revenue reaching about $91 million and gross margin increasing to 56%.
Jun 3, 2026, 20:05 UTC
Iovance Biotherapeutics received regulatory approval from Australian authorities for its T cell therapy Amtagvi (lifileucel) to treat advanced melanoma.
Source:Jun 1, 2026, 16:32 UTC
Iovance Biotherapeutics obtained FDA clearance of an Investigational New Drug application for IOV-5001, extending its cell therapy platform into solid tumors.
Source: